Okami Medical – Weekly Recap

Okami Medical is the focus of this weekly recap, highlighting continued progress for its LOBO embolization platform across real-world cases and conference activity. The company showcased clinical use of LOBO in a renal arteriovenous malformation, underscoring rapid vessel occlusion with a single device per vessel.

In that case, interventional radiologist Dr. Mohammed Loya used LOBO-9 delivered via the SENDERO MAX platform, then telescoped a 2.8 microcatheter through SENDERO MAX to deploy a LOBO-3 in a second feeding branch. The workflow suggests efficiency in complex procedures, with potential economic advantages if fewer devices are required per case.

These results build on prior exposure of LOBO in high-acuity settings, including a recent complex pulmonary aneurysm case in a pregnant patient, where multiple LOBO sizes were used to achieve rapid occlusion. Collectively, such case-based evidence may help strengthen Okami Medical’s clinical credibility and support broader adoption among interventional radiologists.

Okami Medical also emphasized its LOBO HDBRAID Vascular Occluder ahead of GEST 2026 in New York, a key endovascular conference. The device is promoted as the first and only solution designed for complete vascular occlusion with a focus on deliverability and stability in complex peripheral embolization cases.

At GEST 2026, the company plans to showcase LOBO HDBRAID at Booth 114 and participate in educational programming, including hands-on workshops and masterclasses on coils, plugs, and stent grafts. This presence highlights a strategy centered on physician training and engagement, aimed at increasing comfort with LOBO technology in challenging procedures.

From a financial and strategic perspective, increased clinical utilization, positive case reports, and targeted conference marketing could enhance Okami Medical’s positioning in the embolization and interventional radiology markets. While broader clinical data and reimbursement developments remain important, this week’s news reflects steady momentum for the LOBO platform and reinforces the company’s focus on complex vascular interventions.